Shuai Li

Shuai Li is a Senior Associate at WI Harper Group, based in the firm's Beijing office, where he focuses on healthcare investment. His profile is notable for the depth of his scientific background: he brings roughly two years of venture-capital experience alongside approximately eight years of academic research in the biomedical and pharmaceutical fields, which underpins his diligence work on life-sciences and healthcare deals. He holds a doctorate (Ph.D.), with his research background rooted in biomedical science.

WI Harper Group, the firm he works for, is one of the pioneering cross-border venture capital firms in Greater China. Founded in 1993, it was among the earliest VC firms to enter the Chinese market — at a time when the concept of "venture capital" was still largely untested there. The firm operates from strategic offices in San Francisco, Beijing, and Taipei, manages over $1 billion in assets, has backed more than 400 companies, and has recorded more than 100 IPO and M&A exits. It was named one of "China's Top 100 Venture Capital Funds" by the China-FOF Alliance in 2019.

Within WI Harper's investment team structure — which runs from Associates and Senior Associates up through Principals, Partners, and Managing Partners — Shuai Li sits at the Senior Associate level, contributing to sourcing, due diligence, and portfolio support with a specialization in the firm's healthcare and biotech verticals. His combination of hands-on laboratory/research experience and investing work makes him a technical evaluator of early-stage life-sciences companies rather than a generalist.

• Sector specialization: Healthcare, biotech, and biomedical/pharmaceutical companies — the areas where his eight years of academic research give him technical evaluation depth.
• Stage: Aligned with WI Harper's mandate, which spans seed, early, and later-stage companies; his associate-level work centers on early-stage sourcing and diligence.
• Firm-level thesis: WI Harper positions itself to "back the bold" across breakthrough sectors — healthcare, biotech, AI, robotics, IoT, fintech, insurtech, blockchain, sustainability, media, and LOHAS/wellness — investing cross-border between the US and Greater China.
• What likely earns a "yes": Given his scientific training, defensible science/technology, strong clinical or research validation, and a credible technical team are natural fit signals for the healthcare deals he evaluates.